Taysha reports FY2025 net loss $109M; TSHA-102 pivotal trial dosing on track to complete Q2 2026

Taysha Gene Therapies, Inc.

Net loss $109.0M ($0.34/share) vs $89.3M ($0.36) in 2024; R&D expenses rose to $86.4M.
Cash $319.8M as of Dec 31, 2025; raised $50M via ATM in Q4; expects funding into 2028.
Dosed multiple Rett patients in REVEAL pivotal trial; enrollment advancing, on track to complete dosing in Q2 2026.
FDA cleared ASPIRE trial in patients aged 2 to <4 yrs; alignment on CMC and data pooling for BLA submission.
TSHA-102 generally well tolerated; no treatment-related SAEs or DLTs as of March 2026 data cutoff.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Taysha Gene Therapies, Inc. reported financial results for fiscal year ended December 31, 2025.

Period: fiscal year ended December 31, 2025
Result: reported results

Exact text from the filing

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

View on SEC.gov

Browse all earnings releases →

Taysha Gene Therapies, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-115177

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.